The Effects of Kynurenine Aminotransferase Inhibition in People With Schizophrenia (TrypNAC-II)
Sponsor: University of Maryland, Baltimore
Listed as NCT04013555, this PHASE1/PHASE2 trial focuses on Schizoaffective Disorder and Schizophrenia and remains completed. Sponsored by University of Maryland, Baltimore, it has been updated 17 times since 2020, reflecting substantial change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Status Flow
Change History
17 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE1/PHASE2
-
Apr 2025 — Feb 2026 [monthly]
Completed PHASE1/PHASE2
-
Dec 2024 — Apr 2025 [monthly]
Completed PHASE1/PHASE2
Status: Recruiting → Completed
-
Sep 2024 — Dec 2024 [monthly]
Recruiting PHASE1/PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
▶ Show 12 earlier versions
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2024 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2023 — Jan 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2022 — Jan 2023 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — Jan 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2020 — Nov 2020 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2020 — Mar 2020 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Dec 2019 — Jan 2020 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Nov 2019 — Dec 2019 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Sep 2019 — Nov 2019 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Aug 2019 — Sep 2019 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University of Maryland, Baltimore
For direct contact, visit the study record on ClinicalTrials.gov .